Seeking Alpha EN

Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M

Mar 09, 2026 &03230909202631; 20:23 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Coherus BioSciences reported disappointing Q3 results with non-GAAP EPS of -$0.34, missing expectations by $0.03, and revenue of $12.7M falling short by $1.39M. The significant revenue miss indicates operational challenges and potential market share losses in the biopharmaceutical sector.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

CHRS

CHRSStock

Expected to decline

Earnings miss on both EPS and revenue metrics signals operational underperformance and potential guidance reduction

⇅

S&P 500

^GSPCIndex

High volatility expected

Biotech sector weakness may create minor headwinds for broader market sentiment

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing exposure to CHRS or establishing short positions. Monitor upcoming guidance revision and cash runway disclosures, as biotech companies with revenue misses often face significant stock repricing. Watch for insider selling activity.

KEY SIGNALS

Double earnings miss (EPS and revenue)Negative non-GAAP EPS indicates profitability challengesRevenue shortfall of 10% suggests demand weaknessPotential cash burn acceleration concerns

SECTORS INVOLVED

BiotechnologyHealthcarePharmaceuticals

Analysis generated on Mar 10, 2026 at 00:26 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M

RELATED INTELLIGENCE